{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:00:36Z","timestamp":1781110836376,"version":"3.54.1"},"reference-count":212,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2003,2]]},"DOI":"10.1007\/s00109-002-0413-8","type":"journal-article","created":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T18:52:55Z","timestamp":1478026375000},"page":"71-86","source":"Crossref","is-referenced-by-count":23,"title":["Therapeutic vaccination with tumor cells that engage CD137"],"prefix":"10.1007","volume":"81","author":[{"given":"Karl Erik","family":"Hellstrom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingegerd","family":"Hellstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,2,8]]},"reference":[{"key":"0413_CR1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1073\/pnas.60.4.1231","volume":"60","author":"Hellstrom","year":"1968","unstructured":"Hellstrom I, Hellstrom KE, Pierce GE, Bill AH (1968) Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc Natl Acad Sci U S A 60:1231\u20131238","journal-title":"Proc Natl Acad Sci U S A"},{"key":"0413_CR2","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/2201352a0","volume":"220","author":"Hellstrom","year":"1968","unstructured":"Hellstrom I, Hellstrom KE, Pierce GE, Yang JP (1968) Cellular and humoral immunity to different types of human neoplasms. Nature 220:1352\u20131354","journal-title":"Nature"},{"key":"0413_CR3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ijc.2910050303","volume":"5","author":"Bubenik","year":"1970","unstructured":"Bubenik J, Perlmann P, Helmstein K, Moberger G (1970) Cellular and humoral immune responses to human urinary bladder carcinomas. Int J Cancer 5:310\u2013319","journal-title":"Int J Cancer"},{"key":"0413_CR4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ijc.2910120108","volume":"12","author":"Baldwin","year":"1973","unstructured":"Baldwin RW, Embleton MJ, Jones JS, Langman MJS (1973) Cell mediated and humoral immune reactions to human tumors. Int J Cancer 12:73\u201383","journal-title":"Int J Cancer"},{"key":"0413_CR5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/ijc.2910140103","volume":"14","author":"Cochran","year":"1974","unstructured":"Cochran AJ, Grant RM, Spilg WG, et al (1974) Sensitization to tumour-associated antigens in human breast carcinoma. Int J Cancer 14:19\u201325","journal-title":"Int J Cancer"},{"key":"0413_CR6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0065-230X(08)60055-X","volume":"19","author":"Herberman","year":"1974","unstructured":"Herberman RB (1974) Cell-mediated immunity to tumor cells. Adv Cancer Res 19:207\u2013263","journal-title":"Adv Cancer Res"},{"key":"0413_CR7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jnci\/55.1.19","volume":"55","author":"McCoy","year":"1975","unstructured":"McCoy JL, Jerome LF, Dean JH, et al (1975) Inhibition of leukocyte migration by tumor-associated antigens in soluble extracts of human malignant melanoma. J Natl Cancer Inst 55:19\u201323","journal-title":"J Natl Cancer Inst"},{"key":"0413_CR8","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/jnci\/59.5.1413","volume":"59","author":"McCoy","year":"1977","unstructured":"McCoy JL, Jerome LF, Cannon GB, Weese JL, Herberman RB (1977) Reactivity of lung cancer patients in leukocyte migration inhibition assays to 3-M potassium chloride extracts of fresh tumor and tissue-cultured cells derived from lung cancer. J Natl Cancer Inst 59:1413\u20131418","journal-title":"J Natl Cancer Inst"},{"key":"0413_CR9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ijc.2910170206","volume":"17","author":"de Vries","year":"1976","unstructured":"de Vries JE, Rumke P (1976) Tumour-associated lymphocyte cytotoxicity superimposed on \"spontaneous\" cytotoxicity in melanoma patients. Int J Cancer 17:182\u2013190","journal-title":"Int J Cancer"},{"key":"0413_CR10","doi-asserted-by":"crossref","first-page":"510","DOI":"10.4049\/jimmunol.132.1.510","volume":"132","author":"de Vries","year":"1984","unstructured":"de Vries JE, Spits H (1984) Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity. J Immunol 132:510\u2013519","journal-title":"J Immunol"},{"key":"0413_CR11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ijc.2910190409","volume":"19","author":"Cannon","year":"1977","unstructured":"Cannon GB, Bonnard GD, Djeu J, West WH, Herberman RB (1977) Relationship of human natural lymphocyte-mediated cytotoxicity to cytotoxicity of breast-cancer-derived target cells. Int J Cancer 19:487\u2013497","journal-title":"Int J Cancer"},{"key":"0413_CR12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00002371-199803000-00005","volume":"21","author":"Hellstrom","year":"1998","unstructured":"Hellstrom I, Hellstrom KE (1998) Tumor vaccines\u2014a reality at last? J Immunother 21:119\u2013126","journal-title":"J Immunother"},{"key":"0413_CR13","unstructured":"Wallack MK, Bash J (1992) Vaccinia oncosylates as melanoma vaccines. In: Balch CM (ed) Cutaneous melanoma. Lippincott, Philadelphia, pp 548\u2013550"},{"key":"0413_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev.immunol.12.1.337","volume":"12","author":"Boon","year":"1994","unstructured":"Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337\u2013365","journal-title":"Annu Rev Immunol"},{"key":"0413_CR15","first-page":"97","volume":"187","author":"Melief","year":"1994","unstructured":"Melief CJ, Kast WM (1994) Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides. Ciba Found Symp 187:97\u2013104","journal-title":"Ciba Found Symp"},{"key":"0413_CR16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1600-065X.1995.tb00079.x","volume":"145","author":"Hellstrom","year":"1995","unstructured":"Hellstrom KE, Hellstrom I, Chen L (1995) Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev 145:123\u2013145","journal-title":"Immunol Rev"},{"key":"0413_CR17","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1006\/clim.1999.4819","volume":"95","author":"Pardoll","year":"2000","unstructured":"Pardoll DM (2000) Therapeutic vaccination for cancer. Clin Immunol 95:S44\u2013S62","journal-title":"Clin Immunol"},{"key":"0413_CR18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0065-230X(08)60295-X","volume":"58","author":"Boon","year":"1992","unstructured":"Boon T (1992) Toward a genetic analysis of tumor rejection antigens. Adv Cancer Res 58:177\u2013210","journal-title":"Adv Cancer Res"},{"key":"0413_CR19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.1992.10.2.180","volume":"10","author":"Rosenberg","year":"1992","unstructured":"Rosenberg SA (1992) Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180\u2013199","journal-title":"J Clin Oncol"},{"key":"0413_CR20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1600-065X.1995.tb00076.x","volume":"145","author":"Cheever","year":"1995","unstructured":"Cheever MA, Disis ML, Bernhard H, et al (1995) Immunity to oncogenic proteins. Immunol Rev 145:33\u201359","journal-title":"Immunol Rev"},{"key":"0413_CR21","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1084\/jem.187.8.1163","volume":"187","author":"Old","year":"1998","unstructured":"Old LJ, Chen YT (1998) New paths in human cancer serology. J Exp Med 187:1163\u20131167","journal-title":"J Exp Med"},{"key":"0413_CR22","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/35077246","volume":"411","author":"Rosenberg","year":"2001","unstructured":"Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411:380\u2013384","journal-title":"Nature"},{"key":"0413_CR23","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.0.CO;2-P","volume":"76","author":"Scanlan","year":"1998","unstructured":"Scanlan MJ, Chen YT, Williamson B, et al (1998) Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 76:652\u2013658","journal-title":"Int J Cancer"},{"key":"0413_CR24","doi-asserted-by":"publisher","first-page":"14571","DOI":"10.1073\/pnas.251547298","volume":"98","author":"Nishikawa","year":"2001","unstructured":"Nishikawa H, Tanida K, Ikeda H, et al (2001) Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc Natl Acad Sci U S A 98:14571\u201314576","journal-title":"Proc Natl Acad Sci U S A"},{"key":"0413_CR25","doi-asserted-by":"crossref","unstructured":"Ye C, Savage PA, Lee PP, Davis MM, Greenberg PD (1999) Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 162","DOI":"10.4049\/jimmunol.162.4.2227"},{"key":"0413_CR26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0167-5699(97)80020-5","volume":"18","author":"Boon","year":"1997","unstructured":"Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. Immunol Today 18:267\u2013268","journal-title":"Immunol Today"},{"key":"0413_CR27","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0952-7915(96)80076-8","volume":"8","author":"Pardoll","year":"1996","unstructured":"Pardoll DM (1996) Cancer vaccines: a road map for the next decade. Curr Opin Immunol 8:619\u2013621","journal-title":"Curr Opin Immunol"},{"key":"0413_CR28","doi-asserted-by":"crossref","unstructured":"Hellstrom KE, Hellstrom I (1999) Cancer Vaccines. In: Perlmann P, Wigzell H (eds) Handbook of experimental pharmacology. Springer, Berlin Heidelberg New York, pp 463\u2013478","DOI":"10.1007\/978-3-642-59955-2_17"},{"key":"0413_CR29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ijc.1503","volume":"94","author":"Steinman","year":"2001","unstructured":"Steinman RM, Dhodapkar M (2001) Active immunization against cancer with dendritic cells: the near future. Int J Cancer 94:459\u2013473","journal-title":"Int J Cancer"},{"key":"0413_CR30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","volume":"4","author":"Nestle","year":"1998","unstructured":"Nestle FO, Alijagic S, Gilliet M, et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328\u2013332","journal-title":"Nat Med"},{"key":"0413_CR31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nm0398-321","volume":"4","author":"Rosenberg","year":"1998","unstructured":"Rosenberg SA, Yang JC, Schwartzentruber DJ, et al (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321\u2013327","journal-title":"Nat Med"},{"key":"0413_CR32","first-page":"326","volume":"3","author":"Gross","year":"1943","unstructured":"Gross L (1943) Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res 3:326\u2013333","journal-title":"Cancer Res"},{"key":"0413_CR33","first-page":"835","volume":"13","author":"Foley","year":"1953","unstructured":"Foley EJ (1953) Antigenic properties of methylcholanthrene-induced tumor in mice of the strain of origin. Cancer Res 13:835\u2013837","journal-title":"Cancer Res"},{"key":"0413_CR34","first-page":"769","volume":"18","author":"Prehn","year":"1957","unstructured":"Prehn R, Main D (1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18:769\u2013778","journal-title":"J Natl Cancer Inst"},{"key":"0413_CR35","first-page":"1561","volume":"20","author":"Klein","year":"1960","unstructured":"Klein G, Sj\u00f6gren HO, Klein E, Hellstr\u00f6m KE (1960) Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 20:1561\u20131572","journal-title":"Cancer Res"},{"key":"0413_CR36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/bjc.1976.37","volume":"33","author":"Hewitt","year":"1976","unstructured":"Hewitt HB, Blake ER, Walder AS (1976) A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 33:241\u2013259","journal-title":"Br J Cancer"},{"key":"0413_CR37","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1073\/pnas.93.6.2557","volume":"93","author":"Malins","year":"1996","unstructured":"Malins DC, Polissar NL, Gunselman SJ (1996) Progression of human breast cancers to the metastatic state is linked to hydroxyl radical-induced DNA damage. Proc Natl Acad Sci USA 93:2557\u20132563","journal-title":"Proc Natl Acad Sci USA"},{"key":"0413_CR38","first-page":"2477","volume":"28","author":"Vaage","year":"1968","unstructured":"Vaage J (1968) Nonvirus-associated antigens in virus-induced mouse mammary tumors. Cancer Res 28:2477\u20132483","journal-title":"Cancer Res"},{"key":"0413_CR39","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1084\/jem.144.4.873","volume":"144","author":"Shiku","year":"1976","unstructured":"Shiku H, Takahashi T, Oettgen HF (1976) Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens. J Exp Med 144:873\u2013881","journal-title":"J Exp Med"},{"key":"0413_CR40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nm0196-52","volume":"2","author":"Hsu","year":"1996","unstructured":"Hsu FJ, Benike C, Fagnoni F, et al (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52\u201358","journal-title":"Nat Med"},{"key":"0413_CR41","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1073\/pnas.91.8.3171","volume":"91","author":"Noguchi","year":"1994","unstructured":"Noguchi Y, Chen Y-T, Old LJ (1994) A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc Natl Acad Sci U S A 91:3171\u20133175","journal-title":"Proc Natl Acad Sci U S A"},{"key":"0413_CR42","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.7652577","volume":"269","author":"Wolfel","year":"1995","unstructured":"Wolfel T, Hauer M, Schneider J, et al (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281\u20131284","journal-title":"Science"},{"key":"0413_CR43","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1096\/fasebj.3.6.2649402","volume":"3","author":"Hellstrom","year":"1989","unstructured":"Hellstrom KE, Hellstrom I (1989) Oncogene-associated tumor antigens as targets for immunotherapy. FASEB J 3:1715\u20131722","journal-title":"FASEB J"},{"key":"0413_CR44","first-page":"329","volume":"21","author":"Sjogren","year":"1961","unstructured":"Sjogren HL, Hellstrom I, Klein G (1961) Transplantation of polyoma virus-induced tumors in mice. Cancer Res 21:329\u2013337","journal-title":"Cancer Res"},{"key":"0413_CR45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.115.1.181","volume":"115","author":"Habel","year":"1962","unstructured":"Habel K (1962) Immunological determinants of polyoma virus oncogenesis. J Exp Med 115:181\u2013193","journal-title":"J Exp Med"},{"key":"0413_CR46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000391374","volume":"6","author":"Sjogren","year":"1965","unstructured":"Sjogren HO (1965) Transplantation methods as a tool for detection of tumor-specific antigens. Prog Exp Tumor Res 6:289\u2013322","journal-title":"Prog Exp Tumor Res"},{"key":"0413_CR47","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1073\/pnas.88.1.110","volume":"88","author":"Chen","year":"1991","unstructured":"Chen LP, Thomas EK, Hu SL, Hellstr\u00f6m I, Hellstr\u00f6m KE (1991) Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci U S A 88:110\u2013114","journal-title":"Proc Natl Acad Sci U S A"},{"key":"0413_CR48","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.4049\/jimmunol.148.8.2617","volume":"148","author":"Chen","year":"1992","unstructured":"Chen L, Mizuno MT, Singhal MC, et al (1992) Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papilloma virus type 16. J Immunol 148:2617\u20132621","journal-title":"J Immunol"},{"key":"0413_CR49","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","volume":"254","author":"Bruggen","year":"1991","unstructured":"Bruggen P van der, Traversari C, Chomez P, et al (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643\u20131647","journal-title":"Science"},{"key":"0413_CR50","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1084\/jem.183.3.725","volume":"183","author":"Boon","year":"1996","unstructured":"Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725\u2013729","journal-title":"J Exp Med"},{"key":"0413_CR51","unstructured":"Rosenberg SA (2000) Identification of cancer antigens: impact on development of cancer immunotherapies. Cancer J Sci Am 6 [Suppl 3]:S200\u2013S207"},{"key":"0413_CR52","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1084\/jem.122.3.467","volume":"122","author":"Gold","year":"1965","unstructured":"Gold P, Freedman SO (1965) Specific carcinoembryonic antigens of the human digestive system. J Exp Med 122:467\u2013481","journal-title":"J Exp Med"},{"key":"0413_CR53","first-page":"6944","volume":"62","author":"Greiner","year":"2002","unstructured":"Greiner JW, Zeytin H, Anver MR, Schlom J (2002) Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 62:6944\u20136951","journal-title":"Cancer Res"},{"key":"0413_CR54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1600-065X.1995.tb00077.x","volume":"145","author":"Finn","year":"1995","unstructured":"Finn OJ, Jerome KR, Henderson RA, et al (1995) MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 145:61\u201389","journal-title":"Immunol Rev"},{"key":"0413_CR55","unstructured":"Rosenberg SA (2000) The identification of cancer antigens: impact on the development of cancer vaccines. Cancer J Sci Am 6 [Suppl 2]:S142\u2013s149"},{"key":"0413_CR56","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.4049\/jimmunol.146.9.3235","volume":"146","author":"Kahn","year":"1991","unstructured":"Kahn M, Sugawara H, McGowan P, et al (1991) CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J Immunol 146:3235\u20133241","journal-title":"J Immunol"},{"key":"0413_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.2910070102","volume":"7","author":"Hellstrom","year":"1971","unstructured":"Hellstrom I, Hellstrom KE, Sjogren HO, Werner GA (1971) Demonstration of cell-mediated immunity to human neoplasms of various histological types. Int J Cancer 7:1\u201316","journal-title":"Int J Cancer"},{"key":"0413_CR58","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ijc.2910180506","volume":"18","author":"Kadish","year":"1976","unstructured":"Kadish AS, Marcus DM, Bloom BR (1976) Inhibition of leukocyte migration inhibitin by human breast cancer-associated antigens. Int J Cancer 18:581\u2013586","journal-title":"Int J Cancer"},{"key":"0413_CR59","first-page":"233","volume":"64","author":"Morton","year":"1968","unstructured":"Morton DL, Malmgren RA, Holmes EC, Ketcham A (1968) Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 64:233\u2013240","journal-title":"Surgery"},{"key":"0413_CR60","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(02)07746-2","volume":"359","author":"Petricoin","year":"2002","unstructured":"Petricoin III EF, Ardekani AM, Hitt BA, et al (2002) Use of proteomic patterns in serum to identify ovarian cancer. The Lancet 359:572\u2013577","journal-title":"The Lancet"},{"key":"0413_CR61","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0065-230X(08)60331-0","volume":"12","author":"Hellstrom","year":"1969","unstructured":"Hellstrom KE, Hellstrom I (1969) Cellular immunity against tumor specific antigens. Adv Cancer Res 12:167\u2013223","journal-title":"Adv Cancer Res"},{"key":"0413_CR62","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0065-2776(08)60778-6","volume":"49","author":"Greenberg","year":"1991","unstructured":"Greenberg PD (1991) Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281\u2013355","journal-title":"Adv Immunol"},{"key":"0413_CR63","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-065X.1995.tb00081.x","volume":"145","author":"Melief","year":"1995","unstructured":"Melief CJ, Kast WM (1995) T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 145:167\u2013177","journal-title":"Immunol Rev"},{"key":"0413_CR64","doi-asserted-by":"crossref","unstructured":"Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 11:11","DOI":"10.1073\/pnas.242600099"},{"key":"0413_CR65","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nm0402-343","volume":"8","author":"Ye","year":"2002","unstructured":"Ye Z, Hellstrom I, Hayden-Ledbetter M, Dahlin A, Ledbetter JA, Hellstrom KE (2002) Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med 8:343\u2013348","journal-title":"Nat Med"},{"key":"0413_CR66","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/0092-8674(89)90044-5","volume":"57","author":"Schwartz","year":"1989","unstructured":"Schwartz RH (1989) Acquisition of immunologic self-tolerance. Cell 57:1073\u20131081","journal-title":"Cell"},{"key":"0413_CR67","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev.immunol.11.1.191","volume":"11","author":"Linsley","year":"1993","unstructured":"Linsley PS, Ledbetter JA (1993) The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11:191\u2013212","journal-title":"Annu Rev Immunol"},{"key":"0413_CR68","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1073\/pnas.86.4.1333","volume":"86","author":"Thompson","year":"1989","unstructured":"Thompson CB, Lindsten T, Ledbetter JA, et al (1989) CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines\/cytokines. Proc Natl Acad Sci U S A 86:1333\u20131337","journal-title":"Proc Natl Acad Sci U S A"},{"key":"0413_CR69","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0092-8674(05)80059-5","volume":"71","author":"Chen","year":"1992","unstructured":"Chen L, Ashe S, Brady WA, et al (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093\u20131102","journal-title":"Cell"},{"key":"0413_CR70","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.4049\/jimmunol.154.6.2794","volume":"154","author":"Yang","year":"1995","unstructured":"Yang G, Hellstr\u00f6m KE, Hellstr\u00f6m I, Chen L (1995) Antitumor immunity elicited by tumor cells transfected with B7\u20132, a second ligand for CD28\/CTLA-4 costimulatory molecules. J Immunol 154:2794\u20132800","journal-title":"J Immunol"},{"key":"0413_CR71","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1126\/science.7513904","volume":"264","author":"Huang","year":"1994","unstructured":"Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961\u2013965","journal-title":"Science"},{"key":"0413_CR72","doi-asserted-by":"crossref","first-page":"851","DOI":"10.4049\/jimmunol.158.2.851","volume":"158","author":"Yang","year":"1997","unstructured":"Yang G, Mizuno MT, Hellstr\u00f6m KE, Chen L (1997) B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes. J Immunol 158:851\u2013858","journal-title":"J Immunol"},{"key":"0413_CR73","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/35082583","volume":"411","author":"Ochsenbein","year":"2001","unstructured":"Ochsenbein AF, Sierro S, Odermatt B, et al (2001) Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411:1058\u20131064","journal-title":"Nature"},{"key":"0413_CR74","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1128\/JVI.71.5.3998-4004.1997","volume":"71","author":"Melero","year":"1997","unstructured":"Melero I, Singhal MC, McGowan P, et al (1997) Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J Virol 71:3998\u20134004","journal-title":"J Virol"},{"key":"0413_CR75","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.me.15.020164.001123","volume":"15","author":"Old","year":"1964","unstructured":"Old LJ, Boyse EA (1964) Immunology of experimental tumors. Annu Rev Med 15:167\u2013186","journal-title":"Annu Rev Med"},{"key":"0413_CR76","doi-asserted-by":"publisher","first-page":"9482","DOI":"10.1073\/pnas.95.16.9482","volume":"95","author":"Fields","year":"1998","unstructured":"Fields RC, Shimizu J, Mule' JJ (1998) Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 95:9482\u20139487","journal-title":"Proc Natl Acad Sci U S A"},{"key":"0413_CR77","first-page":"8513","volume":"61","author":"Geiger","year":"2001","unstructured":"Geiger JD, Hutchinson RJ, Hohenkirk LF, et al (2001) Vaccination of pediatric solid tumor patients with tumor-lysate pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 61:8513\u20138519","journal-title":"Cancer Res"},{"key":"0413_CR78","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1084\/jem.179.2.523","volume":"179","author":"Chen","year":"1994","unstructured":"Chen L, McGowan P, Ashe S, et al (1994) Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179:523\u2013532","journal-title":"J Exp Med"},{"key":"0413_CR79","first-page":"6477","volume":"54","author":"Townsend","year":"1994","unstructured":"Townsend SE, Su FW, Atherton JM, Allison JP (1994) Specificity and longevity of antitumor immune responses induced by B7\u2013 transfected tumors. Cancer Res 54:6477\u20136483","journal-title":"Cancer Res"},{"key":"0413_CR80","first-page":"425","volume":"JA","author":"Clark","year":"1994","unstructured":"Clark EA, Ledbetter JA (1994) How B and T cells talk to each other Nature 367:425\u2013428","journal-title":"Ledbetter"},{"key":"0413_CR81","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.4049\/jimmunol.152.4.1523","volume":"152","author":"Cayabyab","year":"1994","unstructured":"Cayabyab M, Phillips JH, Lanier LL (1994) CD40 preferentially costimulates activation of CD4+ T lymphocytes. J Immunol 152:1523\u20131531","journal-title":"J Immunol"},{"key":"0413_CR82","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev.immunol.16.1.111","volume":"16","author":"Grewal","year":"1998","unstructured":"Grewal IS, Flavell RA (1998) CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16:111\u2013135","journal-title":"Annu Rev Immunol"},{"key":"0413_CR83","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/5505","volume":"5","author":"French","year":"1999","unstructured":"French RR, Chan HT, Tutt AL, Glennie MJ (1999) cD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 5:548\u2013553","journal-title":"Nat Med"},{"key":"0413_CR84","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/10495","volume":"5","author":"Diehl","year":"1999","unstructured":"Diehl L, den Boer AT, Schoenberger SP, et al (1999) CD40 activation in vivo overcomes peptide-induced periphereal cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 5:774\u2013779","journal-title":"Nat Med"},{"key":"0413_CR85","first-page":"3094","volume":"58","author":"Schoenberger","year":"1998","unstructured":"Schoenberger SP, Jonges LE, Mooijaart RJ, et al (1998) Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. Cancer Res 58:3094\u20133100","journal-title":"Cancer Res"},{"key":"0413_CR86","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-1759(00)00349-5","volume":"248","author":"Todryk","year":"2001","unstructured":"Todryk SM, Tutt AL, Green HA, et al (2001) CD40 ligation for immunotherapy of solid tumors. J Immunol Methods 248:139\u2013147","journal-title":"J Immunol Methods"},{"key":"0413_CR87","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1084\/jem.183.2.639","volume":"183","author":"Li","year":"1996","unstructured":"Li Y, Hellstr\u00f6m KE, Ashe Newby S, Chen L (1996) Costimulation by CD48 and B7\u20131 induces immunity against poorly immunogenic tumors. J Exp Med 183:639\u2013644","journal-title":"J Exp Med"},{"key":"0413_CR88","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1084\/jem.194.9.1339","volume":"194","author":"Liu","year":"2001","unstructured":"Liu X, Bai XF, Wen J, et al (2001) B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8 (+) T lymphocytes in vivo. J Exp Med 194:1339\u20131348","journal-title":"J Exp Med"},{"key":"0413_CR89","unstructured":"Loetze MT, Hellerstedt B, Stolinski L, et al (1997) The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J Sci Am [Suppl 1]:S109\u2013S114"},{"key":"0413_CR90","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","volume":"1","author":"Walunas","year":"1994","unstructured":"Walunas TL, Lenschow DJ, Bakker CY, et al (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405\u2013413","journal-title":"Immunity"},{"key":"0413_CR91","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1084\/jem.183.6.2533","volume":"183","author":"Krummel","year":"1996","unstructured":"Krummel MF, Allison JP (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183:2533\u20132540","journal-title":"J Exp Med"},{"key":"0413_CR92","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734\u20131736","journal-title":"Science"},{"key":"0413_CR93","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/ni0702-611","volume":"3","author":"Egen","year":"2002","unstructured":"Egen JG, Kuhns MS, Allison JP (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3:611\u2013618","journal-title":"Nat Immunol"},{"key":"0413_CR94","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1600-065X.1996.tb00926.x","volume":"153","author":"Winberg","year":"1996","unstructured":"Winberg G, Grosmaire LS, Klussman K, et al (1996) Surface expression of CD28 single chain Fv for costimulation by tumor cells. Immunol Rev 153:209\u2013223","journal-title":"Immunol Rev"},{"key":"0413_CR95","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0952-7915(97)80136-7","volume":"9","author":"Hayden","year":"1997","unstructured":"Hayden MS, Gilliland LK, Ledbetter JA (1997) Antibody engineering. Curr Opin Immunol 9:201\u2013212","journal-title":"Curr Opin Immunol"},{"key":"0413_CR96","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1399-0039.1996.tb02642.x","volume":"48","author":"Hayden","year":"1996","unstructured":"Hayden MS, Grosmaire LS, Norris NA, et al (1996) Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen. Tissue Antigens 48:242\u2013254","journal-title":"Tissue Antigens"},{"key":"0413_CR97","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s002620050586","volume":"48","author":"Kiessling","year":"1999","unstructured":"Kiessling R, Wasserman K, Horiguchi S, et al (1999) Tumor-induced immune dysfunction. Cancer Immunol Immunother 48:353\u2013362","journal-title":"Cancer Immunol Immunother"},{"key":"0413_CR98","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1126\/science.1465616","volume":"258","author":"Mizoguchi","year":"1992","unstructured":"Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795\u20131798","journal-title":"Science"},{"key":"0413_CR99","first-page":"5610","volume":"53","author":"Nakagomi","year":"1993","unstructured":"Nakagomi H, Petersson M, Magnusson I, et al (1993) Decreased expression of the signal-transducing z chains in tumor-infiltrating T cells and NK cells of patients with colorectal carcinoma. Cancer Res 53:5610\u20135612","journal-title":"Cancer Res"},{"key":"0413_CR100","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1073\/pnas.62.2.362","volume":"62","author":"Hellstrom","year":"1969","unstructured":"Hellstrom I, Hellstrom KE, Evans CA, Heppner GH, Pierce GE, Yang JP (1969) Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens. Proc Natl Acad Sci U S A 62:362\u2013369","journal-title":"Proc Natl Acad Sci U S A"},{"key":"0413_CR101","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0065-2776(08)60311-9","volume":"18","author":"Hellstrom","year":"1974","unstructured":"Hellstrom KE, Hellstrom I (1974) Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol 18:209\u2013277","journal-title":"Adv Immunol"},{"key":"0413_CR102","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ijc.2910230315","volume":"23","author":"Hellstrom","year":"1979","unstructured":"Hellstrom KE, Hellstrom I (1979) Enhancement of tumor outgrowth by tumor-associated blocking factors. Int J Cancer 23:366\u2013373","journal-title":"Int J Cancer"},{"key":"0413_CR103","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1073\/pnas.68.6.1372","volume":"68","author":"Sjogren","year":"1971","unstructured":"Sjogren HO, Hellstrom I, Bansal SC, Hellstrom KE (1971) Suggestive evidence that the \"blocking antibodies\" of tumor-bearing individuals may be antigen-antibody complexes. Proc Natl Acad Sci U S A 68:1372\u20131375","journal-title":"Proc Natl Acad Sci U S A"},{"key":"0413_CR104","first-page":"193","volume":"32","author":"Vaage","year":"1972","unstructured":"Vaage J (1972) Specific desensitizationof resistance against a syngeneic methylcholanthrene-induced sarcoma in C3Hf mice. Cancer Res 32:193\u2013\u2013199","journal-title":"Cancer Res"},{"key":"0413_CR105","first-page":"2077","volume":"34","author":"Alexander","year":"1974","unstructured":"Alexander P (1974) Escape from immune destruction by the host through shedding of surface antigens: is this a characteristic shared by malignant and embryonic cells? Cancer Res 34:2077\u20132082","journal-title":"Cancer Res"},{"key":"0413_CR106","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1083\/jcb.140.1.17","volume":"140","author":"Gabathuler","year":"1998","unstructured":"Gabathuler R, Alimonti J, Zhang QJ, Kolaitis G, Reid G, Jefferies WA (1998) Surrogate antigen processing mediated by TAP-dependent antigenic peptide secretion. J Cell Biol 140:17\u201327","journal-title":"J Cell Biol"},{"key":"0413_CR107","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/sj.neo.7900140","volume":"3","author":"Nelson","year":"2001","unstructured":"Nelson MB, Nyhus JK, Oravecz-Wilson KI, Barbera-Guillem E (2001) Tumor cells express FcgammaRI which contributes to tumor cell growth and a metastatic phenotype. Neoplasia 3:115\u2013124","journal-title":"Neoplasia"},{"key":"0413_CR108","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1046\/j.1365-2249.2001.01609.x","volume":"125","author":"Barrionuevo","year":"2001","unstructured":"Barrionuevo P, Beigier-Bompadre M, De La Barrera S, et al (2001) Immune complexes (IC) down-regulate the basal and interferon-gamma-induced expression of MHC class II on human monocytes. Clin Exp Immunol 125:251\u2013257","journal-title":"Clin Exp Immunol"},{"key":"0413_CR109","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1006\/cimm.1996.0139","volume":"170","author":"Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, Ciernik IF, Carbone DP (1996) Dendritic cells in antitumor immune responses. I. defective antigen presentation in tumor-bearing hosts. Cell Immunol 170:101\u2013110","journal-title":"Cell Immunol"},{"key":"0413_CR110","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1006\/cimm.1996.0140","volume":"170","author":"Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP (1996) Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell Immunol 170:111\u2013119","journal-title":"Cell Immunol"},{"key":"0413_CR111","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/250594a0","volume":"250","author":"Gershon","year":"1974","unstructured":"Gershon RK, Mokyr MB, Mitchell MS (1974) Activation of suppressor T cells by tumour cells and specific antibody. Nature 250:594\u2013596","journal-title":"Nature"},{"key":"0413_CR112","first-page":"4605","volume":"74","author":"Hellstrom","year":"1978","unstructured":"Hellstrom KE, Hellstrom I (1978) Evidence that tumor antigens enhance tumor growth in vivo by interacting with a radiosensitive (suppressor?) cell population. Proc Natl Acad Sci U S A 74:4605\u20134609","journal-title":"Proc Natl Acad Sci U S A"},{"key":"0413_CR113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(08)60265-1","volume":"45","author":"North","year":"1985","unstructured":"North RJ (1985) Down-regulation of the antitumor immune response. Adv Cancer Res 45:1\u201343","journal-title":"Adv Cancer Res"},{"key":"0413_CR114","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ijc.2910270410","volume":"27","author":"Hellstrom","year":"1981","unstructured":"Hellstrom KE, Hellstrom I (1981) Cell-mediated suppression of tumor immunity has a nonspecific component. I. Evidence from transplantation tests. Int J Cancer 27:481\u2013485","journal-title":"Int J Cancer"},{"key":"0413_CR115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1040-8428(86)80052-X","volume":"5","author":"Coggin","year":"1986","unstructured":"Coggin JH Jr (1986) The implications of embryonic gene expression in neoplasia. Crit Rev Oncol Hematol 5:37\u201355","journal-title":"Crit Rev Oncol Hematol"},{"key":"0413_CR116","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.4049\/jimmunol.163.10.5211","volume":"163","author":"Shimizu","year":"1999","unstructured":"Shimizu J, Yamazaki S, Sakaguchi M (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211\u20135218","journal-title":"J Immunol"},{"key":"0413_CR117","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/ni759","volume":"3","author":"Shimizu","year":"2002","unstructured":"Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S (2002) Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3:135\u2013142","journal-title":"Nat Immunol"},{"key":"0413_CR118","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4049\/jimmunol.169.5.2756","volume":"169","author":"Liyanage","year":"2002","unstructured":"Liyanage UK, Moore TT, Joo H-G, et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756\u20132761","journal-title":"J Immunol"},{"key":"0413_CR119","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/eji.1830220125","volume":"22","author":"Wilbanks","year":"1992","unstructured":"Wilbanks GA, Mammolenti M, Streilein JW (1992) Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta. Eur J Immunol 22:165\u2013173","journal-title":"Eur J Immunol"},{"key":"0413_CR120","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.4049\/jimmunol.160.5.2089","volume":"160","author":"D'Orazio","year":"1998","unstructured":"D'Orazio TJ, Niederkorn JY (1998) A novel role for TGF-beta and IL-10 in the induction of immune privilege. J Immunol 160:2089\u20132098","journal-title":"J Immunol"},{"key":"0413_CR121","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1084\/jem.188.10.1849","volume":"188","author":"Chen","year":"1998","unstructured":"Chen W, Jin W, Wahl SM (1998) Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4 (+) T cells. J Exp Med 188:1849\u20131857","journal-title":"J Exp Med"},{"key":"0413_CR122","first-page":"92","volume":"215","author":"Allison","year":"1998","unstructured":"Allison JP, Chambers C, Hurwitz A, et al (1998) A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? Novartis Found Symp 215:92\u201398","journal-title":"Novartis Found Symp"},{"key":"0413_CR123","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1084\/jem.194.5.629","volume":"194","author":"Nakamura","year":"2001","unstructured":"Nakamura K, Kitani A, Strober W (2001) Cell contact-dependent immunosuppression by CD4 (+) CD25 (+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 194:629\u2013644","journal-title":"J Exp Med"},{"key":"0413_CR124","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/nm1001-1118","volume":"7","author":"Gorelik","year":"2001","unstructured":"Gorelik L, Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7:1118\u20131122","journal-title":"Nat Med"},{"key":"0413_CR125","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1084\/jem.146.6.1719","volume":"146","author":"Goodwin","year":"1977","unstructured":"Goodwin JS, Bankhurst AD, Messner RP (1977) Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell. J Exp Med 146:1719\u20131734","journal-title":"J Exp Med"},{"key":"0413_CR126","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1006\/cimm.2000.1625","volume":"200","author":"Hegardt","year":"2000","unstructured":"Hegardt P, Widegren B, Sjogren HO (2000) Nitric-oxide-dependent systemic immunosuppression in animals with progressively growing malignant gliomas. Cell Immunol 200:116\u2013127","journal-title":"Cell Immunol"},{"key":"0413_CR127","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1126\/science.274.5291.1363","volume":"274","author":"Hahne","year":"1996","unstructured":"Hahne M, Rimoldi D, Schroter M, et al (1996) Melanoma cell expression of Fas (Apo-1\/CD95) ligand: implications for tumor immune escape. Science 274:1363\u20131366","journal-title":"Science"},{"key":"0413_CR128","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/(SICI)1097-0215(19990820)84:4<339::AID-IJC1>3.0.CO;2-2","volume":"84","author":"Kume","year":"1999","unstructured":"Kume T, Oshima K, Yamashita Y, Shirakusa T, Kikuchi M (1999) Relationship between Fas-ligand expression on carcinoma cell and cytotoxic T-lymphocyte response in lymphoepithelioma-like cancer of the stomach. Int J Cancer 84:339\u2013343","journal-title":"Int J Cancer"},{"key":"0413_CR129","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.4049\/jimmunol.160.11.5669","volume":"160","author":"Bennett","year":"1998","unstructured":"Bennett MW, O'Connell J, O'Sullivan GC, et al (1998) The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160:5669\u20135675","journal-title":"J Immunol"},{"key":"0413_CR130","doi-asserted-by":"publisher","first-page":"6420","DOI":"10.1073\/pnas.94.12.6420","volume":"94","author":"Shiraki","year":"1997","unstructured":"Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H (1997) Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci U S A 94:6420\u20136425","journal-title":"Proc Natl Acad Sci U S A"},{"key":"0413_CR131","unstructured":"Chappell DB, Zaks TZ, Rosenberg SA, Restifo NP (1999) Human melanoma cells do not express Fas (Apo-1\/CD95) ligand. Cancer Res 59:59\u201362"},{"key":"0413_CR132","doi-asserted-by":"crossref","unstructured":"Dong H, Strome SE, Salomao D, et al (2002) Tumor-associated By-H1 promotes T-cell apoptosis. A potential mechanism of immune-evasion. Nat Med 8:793\u2013800","DOI":"10.1038\/nm0902-1039c"},{"key":"0413_CR133","doi-asserted-by":"crossref","unstructured":"Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell metastases of human colonic adenocarcinomas. Nature 419:734\u2013738","DOI":"10.1038\/nature01112"},{"key":"0413_CR134","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1172\/JCI118958","volume":"98","author":"Maeurer","year":"1996","unstructured":"Maeurer MJ, Gollin SM, Martin D, et al (1996) Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1\/Melan-A antigen. J Clin Invest 98:1633\u20131641","journal-title":"J Clin Invest"},{"key":"0413_CR135","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.4049\/jimmunol.151.6.2974","volume":"151","author":"Jefferies","year":"1993","unstructured":"Jefferies WA, Kolaitis G, Gabathuler R (1993) The interferon-gamma-induced recognition of the antigen\u2014processing variant CMT.64 by cytolytic T cells can be replaced by sequential addition of beta2 microglobulin and antigenic peptides. J Immunol 151:2974\u20132985","journal-title":"J Immunol"},{"key":"0413_CR136","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1084\/jem.177.2.265","volume":"177","author":"Restifo","year":"1993","unstructured":"Restifo NP, Esquivel F, Kawakami Y, et al (1993) Identification of human cancers deficient in antigen processing. J Exp Med 177:265\u2013272","journal-title":"J Exp Med"},{"key":"0413_CR137","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0167-5699(96)10075-X","volume":"18","author":"Garrido","year":"1997","unstructured":"Garrido F, Ruiz-Cabello F, Cabrera T, et al (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 18:89\u201395","journal-title":"Immunol Today"},{"key":"0413_CR138","first-page":"3660","volume":"58","author":"Johnsen","year":"1998","unstructured":"Johnsen A, France J, Sy MS, Harding CV (1998) Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer Res 58:3660\u20133667","journal-title":"Cancer Res"},{"key":"0413_CR139","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0167-5699(00)01692-3","volume":"21","author":"Seliger","year":"2000","unstructured":"Seliger B, Maeurer MJ, Ferrone S (2000) Antigen-processing machinery breakdown and tumor growth. Immunol Today 21:455\u2013464","journal-title":"Immunol Today"},{"key":"0413_CR140","first-page":"4941","volume":"55","author":"Porgador","year":"1995","unstructured":"Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L (1995) Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. Cancer Res 55:4941\u20134949","journal-title":"Cancer Res"},{"key":"0413_CR141","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S1357-4310(97)01048-4","volume":"3","author":"Hellstrom","year":"1997","unstructured":"Hellstrom KE, Gladstone P, Hellstrom I (1997) Cancer vaccines: challenges and potential solutions. Mol Med Today 3:286\u2013290","journal-title":"Mol Med Today"},{"key":"0413_CR142","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1126\/science.7863341","volume":"267","author":"K\u00c3\u00a4rre","year":"1995","unstructured":"K\u00e4rre K (1995) Express yourself or die: peptides, MHC molecules, and NK cells. Science 267:978\u2013979","journal-title":"Science"},{"key":"0413_CR143","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1084\/jem.180.4.1415","volume":"180","author":"Gabathuler","year":"1994","unstructured":"Gabathuler R, Reid G, Kolaitis G, Driscoll J, Jefferies WA (1994) Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing. J Exp Med 180:1415\u20131425","journal-title":"J Exp Med"},{"key":"0413_CR144","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/ng0696-210","volume":"13","author":"Chen","year":"1996","unstructured":"Chen HL, Gabrilovich DI, Tampe R, Girgis KR, Nadaf S, Carbone DP (1996) A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet 13:210\u2013213","journal-title":"Nat Genet"},{"key":"0413_CR145","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/75373","volume":"18","author":"Alimonti","year":"2000","unstructured":"Alimonti J, Zhang QJ, Gabathuler R, Reid G, Chen S, Jefferies WA (2000) TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat Biotechnol 18:515\u2013520","journal-title":"Nat Biotechnol"},{"key":"0413_CR146","first-page":"157","volume":"7","author":"Coley","year":"1896","unstructured":"Coley W (1896) Further observations upon the treatment of malignant tumors with the toxins of erysipelas and Bacillus prodigiosus with a report of 160 cases. Bull Johns Hopkins Hosp 7:157","journal-title":"Bull Johns Hopkins Hosp"},{"key":"0413_CR147","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJM196802292780904","volume":"278","author":"Wilson","year":"1968","unstructured":"Wilson RE, Hager EB, Hampers CL, Corson JM, Merrill JP, Murray JE (1968) Immunologic rejection of human cancer transplanted with a renal allograft. N Engl J Med 278:479\u2013483","journal-title":"N Engl J Med"},{"key":"0413_CR148","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00007890-197001000-00021","volume":"9","author":"Matter","year":"1970","unstructured":"Matter B, Zukoski CF, Killen DA, Ginn E (1970) Transplanted carcinoma in an immunosuppressed patient. Transplantation 9:71\u201374","journal-title":"Transplantation"},{"key":"0413_CR149","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","volume":"97","author":"McSweeney","year":"2001","unstructured":"McSweeney PA, et al (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390\u20133400","journal-title":"Blood"},{"key":"0413_CR150","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1056\/NEJM200009143431101","volume":"343","author":"Childs","year":"2000","unstructured":"Childs et al (2000) Regression of metastatic renal cell carcinoma after nonmyeloablative allogeneic peripheral blood stem cell transplantation. N Engl J Med 343:750\u2013758","journal-title":"N Engl J Med"},{"key":"0413_CR151","first-page":"399","volume":"1","author":"Mihich","year":"1987","unstructured":"Mihich E (1987) Modulation of antitumor immune responses. Cancer Detect Prev Suppl 1:399\u2013407","journal-title":"Cancer Detect Prev Suppl"},{"key":"0413_CR152","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1084\/jem.148.3.799","volume":"148","author":"Hellstrom","year":"1978","unstructured":"Hellstrom KE, Hellstrom I, Kant JA, Tamerius JD (1978) Regression and inhibition of sarcoma growth by interference with a radiosensitive T cell population. J Exp Med 148:799\u2013804","journal-title":"J Exp Med"},{"key":"0413_CR153","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1084\/jem.164.5.1652","volume":"164","author":"North","year":"1986","unstructured":"North RJ (1986) Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells. J Exp Med 164:1652\u20131666","journal-title":"J Exp Med"},{"key":"0413_CR154","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1084\/jem.141.3.697","volume":"141","author":"Askenase","year":"1975","unstructured":"Askenase PW, Hayden BJ, Gershon RK (1975) Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J Exp Med 141:697\u2013702","journal-title":"J Exp Med"},{"key":"0413_CR155","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(01)62213-4","volume":"160","author":"Einhorn","year":"1998","unstructured":"Einhorn LH, Donohue JP (1998) Advanced testicular cancer: update for urologists. J Urol 160:1964\u20131969","journal-title":"J Urol"},{"key":"0413_CR156","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1200\/JCO.2000.18.19.3346","volume":"18","author":"Bhatia","year":"2000","unstructured":"Bhatia S, Abonour R, Porcu P, et al (2000) High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18:3346\u20133351","journal-title":"J Clin Oncol"},{"key":"0413_CR157","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1002\/1097-0142(20011201)92:11<2778::AID-CNCR10125>3.0.CO;2-S","volume":"92","author":"Aubry","year":"2001","unstructured":"Aubry F, Satie AP, Rioux-Leclercq N, et al (2001) MAGE-A4, a germ cell specific marker, is expressed differentially in testicular tumors. Cancer 92:2778\u20132785","journal-title":"Cancer"},{"key":"0413_CR158","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/S0022-5347(05)66415-4","volume":"165","author":"Yuasa","year":"2001","unstructured":"Yuasa T, Okamoto K, Kawakami T, Mishina M, Ogawa O, Okada Y (2001) Expression patterns of cancer testis antigens in testicular germ cell tumors and adjacent testicular tissue. J Urol 165:1790\u20131794","journal-title":"J Urol"},{"key":"0413_CR159","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0090-4295(98)00618-9","volume":"53","author":"Hara","year":"1999","unstructured":"Hara I, Hara S, Miyake H, et al (1999) Expression of MAGE genes in testicular germ cell tumors. Urology 53:843\u2013847","journal-title":"Urology"},{"key":"0413_CR160","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/sj.bjc.6690393","volume":"80","author":"Marks","year":"1999","unstructured":"Marks A, Sutherland DR, Bailey D, et al (1999) Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumoours. Br J Cancer 80:569\u2013578","journal-title":"Br J Cancer"},{"key":"0413_CR161","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/00001703-200202000-00006","volume":"14","author":"Kendall","year":"2002","unstructured":"Kendall A, Gilmore R, Newlands E (2002) Chemotherapy for trophoblastic disease: current standards. Curr Opin Obstet Gynecol 14:33\u201338","journal-title":"Curr Opin Obstet Gynecol"},{"key":"0413_CR162","first-page":"451","volume":"47","author":"Lurain","year":"2002","unstructured":"Lurain JR (2002) Advances in management of high-risk gestational trophoblastic tumors. J Reprod Med 47:451\u2013459","journal-title":"J Reprod Med"},{"key":"0413_CR163","doi-asserted-by":"publisher","first-page":"6783","DOI":"10.1073\/pnas.021557498","volume":"98","author":"Hellstrom","year":"2001","unstructured":"Hellstrom I, Ledbetter JA, Scholler N, et al (2001) CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer. Proc Natl Acad Sci U S A 98:6783\u20136788","journal-title":"Proc Natl Acad Sci U S A"},{"key":"0413_CR164","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1084\/jem.20010938","volume":"195","author":"Gerosa","year":"2002","unstructured":"Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G (2002) Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 195:327\u2013333","journal-title":"J Exp Med"},{"key":"0413_CR165","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1084\/jem.20010934","volume":"195","author":"Piccioli","year":"2002","unstructured":"Piccioli D, Sbrana S, Melandri E, Valiante NM (2002) Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 195:335\u2013341","journal-title":"J Exp Med"},{"key":"0413_CR166","doi-asserted-by":"publisher","first-page":"F9","DOI":"10.1084\/jem.20012040","volume":"195","author":"Zitvogel","year":"2002","unstructured":"Zitvogel L (2002) Dendritic and natural killer cells cooperate in the control\/switch of innate immunity. J Exp Med 195:F9\u2013F14","journal-title":"J Exp Med"},{"key":"0413_CR167","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.4049\/jimmunol.159.12.5921","volume":"159","author":"Levine","year":"1997","unstructured":"Levine BL, Bernstein WB, Connors M, et al (1997) Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 159:5921\u20135930","journal-title":"J Immunol"},{"key":"0413_CR168","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00002371-199907000-00007","volume":"22","author":"Garlie","year":"1999","unstructured":"Garlie NK, LeFever AV, Siebenlist RE, Levine BL, June CH, Lum LG (1999) T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. J Immunother 22:336\u2013345","journal-title":"J Immunother"},{"key":"0413_CR169","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/nm794","volume":"8","author":"Niethammer","year":"2002","unstructured":"Niethammer AG, Xiang R, Becker JC, et al (2002) A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8:1369\u20131375","journal-title":"Nat Med"},{"key":"0413_CR170","doi-asserted-by":"crossref","first-page":"9064","DOI":"10.1073\/pnas.95.16.9064","volume":"95","author":"Folkman","year":"1998","unstructured":"Folkman J (1998) Antiangiogenic gene therapy. Proc Natl Acad Sci U S A 95:9064\u20139066","journal-title":"Proc Natl Acad Sci U S A"},{"key":"0413_CR171","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.4049\/jimmunol.168.5.2393","volume":"168","author":"Shibagaki","year":"2002","unstructured":"Shibagaki N, Udey MC (2002) Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol 168:2393\u20132401","journal-title":"J Immunol"},{"key":"0413_CR172","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4049\/jimmunol.164.1.161","volume":"164","author":"Min","year":"2000","unstructured":"Min WP, Gorczynski R, Huang XY, et al (2000) Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol 164:161\u2013167","journal-title":"J Immunol"},{"key":"0413_CR173","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, Chen HL, Girgis KR, et al (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096\u20131103","journal-title":"Nat Med"},{"key":"0413_CR174","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0065-230X(08)60318-8","volume":"62","author":"Srivastava","year":"1993","unstructured":"Srivastava PK (1993) Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. Adv Cancer Res 62:153\u2013177","journal-title":"Adv Cancer Res"},{"key":"0413_CR175","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nri749","volume":"2","author":"Srivastava","year":"2002","unstructured":"Srivastava P (2002) Roles of heat-shock proteins in innate and adoptive immunity. Nat Rev Immunol 2:185\u2013194","journal-title":"Nat Rev Immunol"},{"key":"0413_CR176","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1473-3099(02)00315-8","volume":"2","author":"Kao","year":"2002","unstructured":"Kao JH, Chen DS (2002) Global control of hepatitis B virus infection. Lancet Infect Dis 2:395\u2013403","journal-title":"Lancet Infect Dis"},{"key":"0413_CR177","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/1097-0142(19870515)59:10<1692::AID-CNCR2820591003>3.0.CO;2-F","volume":"59","author":"Hausen","year":"1987","unstructured":"Hausen H zur (1987) Papillomaviruses in human cancer. Cancer 59:1692\u20131696","journal-title":"Cancer"},{"key":"0413_CR178","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1748-5827.1997.tb03339.x","volume":"38","author":"Sparkes","year":"1997","unstructured":"Sparkes AH (1997) Feline leukaemia virus: a review of immunity and vaccination. J Small Anim Pract 38:187\u2013194","journal-title":"J Small Anim Pract"},{"key":"0413_CR179","doi-asserted-by":"publisher","first-page":"14272","DOI":"10.1074\/jbc.272.22.14272","volume":"272","author":"Kwon","year":"1997","unstructured":"Kwon BS et al (1997) A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem 272:14272\u201314276","journal-title":"J Biol Chem"},{"key":"0413_CR180","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1084\/jem.181.3.985","volume":"181","author":"DeBenedette","year":"1995","unstructured":"DeBenedette MA, Chu NR, Pollok KE, et al (1995) Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP. J Exp Med 181:985\u2013992","journal-title":"J Exp Med"},{"key":"0413_CR181","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1084\/jem.186.1.47","volume":"186","author":"Shuford","year":"1997","unstructured":"Shuford WW, Klussman K, Tritchler DD, et al (1997) 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 186:47\u201355","journal-title":"J Exp Med"},{"key":"0413_CR182","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1006\/cimm.1998.1396","volume":"190","author":"Melero","year":"1998","unstructured":"Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L (1998) NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 190:167\u2013172","journal-title":"Cell Immunol"},{"key":"0413_CR183","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/intimm\/12.1.73","volume":"12","author":"Kienzle","year":"2000","unstructured":"Kienzle G, von Kempis J (2000) CD137 (ILA\/4\u20134-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes. Int Immunol 12:73\u201382","journal-title":"Int Immunol"},{"key":"0413_CR184","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/jlb.65.6.829","volume":"65","author":"Langstein","year":"1999","unstructured":"Langstein J, Schwartz H (1999) Identification of CD137 as a potent monocyte survival factor. J Leukoc Biol 65:829\u2013833","journal-title":"J Leukoc Biol"},{"key":"0413_CR185","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/intimm\/14.3.275","volume":"14","author":"Futagawa","year":"2002","unstructured":"Futagawa T, Akiba H, Kodama T, et al (2002) Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 14:275\u2013286","journal-title":"Int Immunol"},{"key":"0413_CR186","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/(SICI)1521-4141(199803)28:03<881::AID-IMMU881>3.0.CO;2-0","volume":"28","author":"Kim","year":"1998","unstructured":"Kim YJ, Kim SH, Mantel P, Kwon BS (1998) Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses. Eur J Immunol 28:881\u2013890","journal-title":"Eur J Immunol"},{"key":"0413_CR187","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.4049\/jimmunol.158.6.2600","volume":"158","author":"Hurtado","year":"1997","unstructured":"Hurtado JC, Kim YJ, Kwon BS (1997) Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol 158:2600\u20132609","journal-title":"J Immunol"},{"key":"0413_CR188","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.4049\/jimmunol.162.9.5037","volume":"162","author":"Takahashi","year":"1999","unstructured":"Takahashi C, Mittler RS, Vella AT (1999) Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 162:5037\u20135040","journal-title":"J Immunol"},{"key":"0413_CR189","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0301-472X(98)00028-9","volume":"27","author":"Tsushima","year":"1999","unstructured":"Tsushima H, Imaizumi Y, Imanishi D, Fuchigami K, Tomonaga M (1999) Fas antigen (CD95) in pure erythroid cell line AS-E2 is induced by interferon-gamma and tumor necrosis factor-alpha and potentiates apoptotic death. Exp Hematol 27:433\u2013440","journal-title":"Exp Hematol"},{"key":"0413_CR190","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0006-2952(98)00154-3","volume":"56","author":"Natoli","year":"1998","unstructured":"Natoli G, Costanzo A, Guido F, Moretti F, Levrero M (1998) Apoptotic, non-apoptotic, and anti-apoptotic pathways of tumor necrosis factor signalling. Biochem Pharmacol 56:915\u2013920","journal-title":"Biochem Pharmacol"},{"key":"0413_CR191","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.4049\/jimmunol.167.5.2671","volume":"167","author":"Zhu","year":"2001","unstructured":"Zhu G, Flies DB, Tamada K, et al (2001) Progressive depletion of peripheral B lymphocytes in 4-1BB (CD137) ligand\/I-Ealpha-transgenic mice. J Immunol 167:2671\u20132676","journal-title":"J Immunol"},{"key":"0413_CR192","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1084\/jem.190.10.1535","volume":"190","author":"Mittler","year":"1999","unstructured":"Mittler RS, Bailey TS, Klussman K, Trailsmith MD, Hoffman MK (1999) Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med 190:1535\u20131540","journal-title":"J Exp Med"},{"key":"0413_CR193","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/00002371-200011000-00002","volume":"23","author":"Hong","year":"2000","unstructured":"Hong HJ et al (2000) A humanized anti-4-1-BB monoclonal antibody suppresses antigen-induced humoral immune response in nonhuman primates. J Immunother 23:613\u2013621","journal-title":"J Immunother"},{"key":"0413_CR194","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm0697-682","volume":"3","author":"Melero","year":"1997","unstructured":"Melero I, Shuford WW, Newby SA, et al (1997) Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3:682\u2013685","journal-title":"Nat Med"},{"key":"0413_CR195","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1172\/JCI200214184","volume":"109","author":"Wilcox","year":"2002","unstructured":"Wilcox RA, Flies DB, Zhu G, et al (2002) Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 109:651\u2013659","journal-title":"J Clin Invest"},{"key":"0413_CR196","first-page":"2031","volume":"61","author":"Kim","year":"2001","unstructured":"Kim JA, Averbook BJ, Chambers K, et al (2001) Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res 61:2031\u20132037","journal-title":"Cancer Res"},{"key":"0413_CR197","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.4049\/jimmunol.167.3.1313","volume":"167","author":"Cannons","year":"2001","unstructured":"Cannons JL, Lau P, Ghumman B, et al (2001) 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol 167:1313\u20131324","journal-title":"J Immunol"},{"key":"0413_CR198","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.4049\/jimmunol.166.5.3174","volume":"166","author":"Blazar","year":"2001","unstructured":"Blazar BR, Kwon BS, Panoskaltsis-Mortari A, Kwak KB, Peschon JJ, Taylor PA (2001) Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J Immunol 166:3174\u20133183","journal-title":"J Immunol"},{"key":"0413_CR199","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/(SICI)1521-4141(199803)28:03<1116::AID-IMMU1116>3.0.CO;2-A","volume":"28","author":"Melero","year":"1998","unstructured":"Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L (1998) Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 28:1116\u20131121","journal-title":"Eur J Immunol"},{"key":"0413_CR200","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1006\/mthe.2000.0086","volume":"2","author":"Chen","year":"2000","unstructured":"Chen SH, Pham-Nguyen KB, Martinet O, et al (2000) Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol Ther 2:39\u201346","journal-title":"Mol Ther"},{"key":"0413_CR201","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1006\/cimm.2001.1804","volume":"210","author":"Guinn","year":"2001","unstructured":"Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH (2001) 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors. Cell Immunol 210:56\u201365","journal-title":"Cell Immunol"},{"key":"0413_CR202","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.4049\/jimmunol.165.5.2903","volume":"165","author":"Salih","year":"2000","unstructured":"Salih HR, Kosowski SG, Haluska VF, et al (2000) Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells. J Immunol 165:2903\u20132910","journal-title":"J Immunol"},{"key":"0413_CR203","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1006\/bbrc.2000.2889","volume":"273","author":"Langstein","year":"2000","unstructured":"Langstein J, Becke FM, Sollner L, et al (2000) Comparative analysis of CD137 and LPS effects on monocyte activation, survival, and proliferation. Biochem Biophys Res Commun 273:117\u2013122","journal-title":"Biochem Biophys Res Commun"},{"key":"0413_CR204","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S0952-7915(00)00191-6","volume":"13","author":"Gallucci","year":"2001","unstructured":"Gallucci S, Matzinger P (2001) Danger signals: SOS to the immune system. Curr Opin Immunol 13:114\u2013119","journal-title":"Curr Opin Immunol"},{"key":"0413_CR205","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0167-5699(95)80033-6","volume":"16","author":"Ferrone","year":"1995","unstructured":"Ferrone S, Marincola FM (1995) Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487\u2013494","journal-title":"Immunol Today"},{"key":"0413_CR206","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1749-6632.1993.tb44018.x","volume":"690","author":"Pardoll","year":"1993","unstructured":"Pardoll DM (1993) Genetically engineered tumor vaccines. Ann N Y Acad Sci 690:301\u2013310","journal-title":"Ann N Y Acad Sci"},{"key":"0413_CR207","doi-asserted-by":"crossref","first-page":"6673","DOI":"10.1038\/sj.onc.1204095","volume":"19","author":"Nestle","year":"2000","unstructured":"Nestle FO (2000) Dendritic cell vaccination for cancer therapy. Oncogene 19:6673\u20136679","journal-title":"Oncogene"},{"key":"0413_CR208","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1172\/JCI200215962","volume":"109","author":"Steinman","year":"2002","unstructured":"Steinman RM, Pope M (2002) Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109:1519\u20131526","journal-title":"J Clin Invest"},{"key":"0413_CR209","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1128\/MCB.16.6.2802","volume":"16","author":"Filippova","year":"1996","unstructured":"Filippova GN, Fagerlie S, Klenova EM, et al (1996) An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Mol Cell Biol 16:2802\u20132813","journal-title":"Mol Cell Biol"},{"key":"0413_CR210","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9","volume":"22","author":"Filippova","year":"1998","unstructured":"Filippova GN, Lindblom A, Meincke LJ, et al (1998) A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers. Genes Chromosomes Cancer 22:26\u201336","journal-title":"Genes Chromosomes Cancer"},{"key":"0413_CR211","doi-asserted-by":"publisher","first-page":"6806","DOI":"10.1073\/pnas.092123699","volume":"99","author":"Loukinov","year":"2002","unstructured":"Loukinov DI, Pugacheva E, Vatolin S, et al (2002) BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A 99:6806\u20136811","journal-title":"Proc Natl Acad Sci U S A"},{"key":"0413_CR212","first-page":"5544","volume":"61","author":"Chomez","year":"2001","unstructured":"Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S (2001) An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 61:5544\u20135551","journal-title":"Cancer Res"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-002-0413-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00109-002-0413-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-002-0413-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-002-0413-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T18:17:19Z","timestamp":1692555439000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00109-002-0413-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":212,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["0413"],"URL":"https:\/\/doi.org\/10.1007\/s00109-002-0413-8","relation":{},"ISSN":["0946-2716"],"issn-type":[{"value":"0946-2716","type":"print"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}